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abstract
Cardio-facio-cutaneous syndrome (CFC) is one of the RASopathies that
bears many clinical features in common with the other syndromes in
this group, most notably Noonan syndrome and Costello syndrome.
CFC is genetically heterogeneous and caused by gene mutations in
the Ras/mitogen-activated protein kinase pathway. The major features
of CFC include characteristic craniofacial dysmorphology, congenital
heart disease, dermatologic abnormalities, growth retardation, and in-
tellectual disability. It is essential that this condition be differentiated
from other RASopathies, as a correct diagnosis is important for appro-
priate medical management and determining recurrence risk. Children
and adults with CFC require multidisciplinary care from specialists, and
the need for comprehensive management has been apparent to families
and health care professionals caring for affected individuals. To address
this need, CFC International, a nonproﬁt family support organization that
provides a forum for information, support, and facilitation of research in
basic medical and social issues affecting individuals with CFC, organized
a consensus conference. Experts in multiple medical specialties pro-
vided clinical management guidelines for pediatricians and other care
providers. These guidelines will assist in an accurate diagnosis of indi-
viduals with CFC, provide best practice recommendations, and facilitate
long-term medical care. Pediatrics 2014;134:e1149–e1162
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Cardio-facio-cutaneous syndrome (CFC)
is a multiple congenital anomaly disor-
der thatbelongstoagroupofsyndromes
known as RASopathies.1 Although CFC
has distinctive characteristics, many of
the clinical features overlapwith 2 other
RASopathies, namely Noonan syndrome
(NS) and Costello syndrome (CS), there-
fore making the diagnosis challenging,
especially in the newborn period. CFC is
an autosomal dominant disorder with
the vast majority of cases arising by
a new mutation of BRAF, MEK1, MEK2 or
rarely, KRAS genes. The most common
ﬁndings include dysmorphic craniofacial
features, congenital heart disease,
dermatologic abnormalities, failure to
thrive, gastrointestinal dysfunction,
neurocognitive delay, and seizures.
Although the worldwide prevalence of
CFC is unknown, the prevalence of CFC
in Japan is estimated at 1 in 810 000
individuals.2
It is often challenging to differentiate
CFC from other RASopathies; therefore,
CFC International convened an inter-
national conference on November 5–6,
2012, composed of health care pro-
viders and physician-scientists with ex-
pertise in CFC to aid in establishing
a correct diagnosis and provide opti-
mum clinical management to patients.
The goal of this conference was to re-
view the most current medical and
scientiﬁc information about CFC, and
develop guidelines for its diagnosis and
clinical management. With this, we set
forth timely recommendations for best
practices and comprehensive medical
management for individuals with CFC
(Table 1).
HISTORY
CFCwasﬁrstreported in1986byReynolds
et al3 and by Baraitser and Patton.4 Eight
individuals were described with distinct
facial features, ectodermal abnormali-
ties, cardiac malformations, and intel-
lectual disability.3 At that time, many
believed that the facial features of CFC
TABLE 1 Management Recommendations for CFC
Clinical Specialty Recommendations
Genetics At risk for CFC baseduponphysical examination, developmental history, andmedical history.
At diagnosis:
• Genetics consultation.
• Genetic testing directed by a geneticist/genetics provider using multigene Ras/MAPK
pathway panel testing (if available). Approximately 80%mutation detection rate for CFC.
• Consider sequential gene testing if panel testing is not available: (1) BRAF, (2)MEK1 and
MEK2, and (3) KRAS
• Parental testing if variant of uncertain signiﬁcance is detected.
• Consider high-resolution chromosome microarray if gene testing is negative.
• If the above testing is negative, the geneticist/genetics provider can determine if exome
sequencing is appropriate.
Ongoing management:
• Annual follow-up with geneticist/genetics provider or specialty Ras pathway clinic.
Cardiovascular At risk for pulmonary stenosis, HCM, septal defects.
At diagnosis:
• Echocardiogram, electrocardiogram.
• Consultation with a cardiologist if murmur present or if clinical features suggest CFC or
other RASopathy.
Ongoing management:
• Cardiology follow-up if cardiac disease found at diagnosis or at each of the age intervals
below. Cardiologist will decide on necessity for cardiac catheterization, interventional
procedures, or surgical procedures depending on the individual cardiac abnormalities
of each patient.
• Infancy up to 1 y: If arrhythmias present, 24-h Holter evaluation.
• Childhood and adolescence (up to 20 y): If no cardiac disease found initially, repeat
echocardiogram every 2–3 y. Measurement of blood pressure at each visit.
• Adulthood (.20 y): Echocardiogram every 3–5 y if no previous heart disease found.
Measurement of blood pressure at each visit.
Dermatologic At risk for keratosis pilaris, ulerythema ophryogenes, eczema, progressive multiple
pigmented nevi, dystrophic nails, lymphedema, hemangiomas, hyperkeratosis, and
generalized hyperpigmentation.
At diagnosis:
• Consultation with a dermatologist.
• Evaluation of hemangiomas.
• Evaluation of pigmented nevi.
• If lymphedema present, referral to vascular specialist/clinic.
Ongoing management:
• Frequent dermatology visits for management of xerosis, hyperkeratosis, and eczema.
• Annual evaluation of pigmented nevi.
• Referral to a podiatrist for dystrophic nails or hyperkeratosis if needed.
• Monitor for lymphedema.
•Meticulous skin care and early treatment of skin infection in the context of lymphedema.
• Sun protection as recommended for the general population (ie, sunscreen; hats).
Neurologic At risk for infantile spasms, seizures, hydrocephalus, type I Chiarimalformation, and other
structural brain anomalies.
At diagnosis:
• Referral to neurologist for a baseline evaluation.
• Families should receive anticipatory guidance about the risk of seizures (infantile
spasms, other seizure types) and other neurologic issues.
• Brain MRI should be obtained in cases of rapid increase in head growth, infantile
spasms, changes in neurologic examination, and regression of skills.
• EEG if there is a suspicion of seizure activity.
• Accurate seizure classiﬁcation with clinical history and EEG to help guide medical
management.
Ongoing management:
• Continued follow-up with neurologist for seizure management (if present).
• In child with infantile spasms, consult with cardiologist for possible steroid
management due to risk of cardiomyopathy.
• If peripheral neuropathy suspected, consult with neurologist for nerve conduction
velocities and electromyogram.
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overlapped with those of NS, and a con-
troversy emerged regarding the delin-
eation of CFC as a new, distinct syndrome
versus a severe form of NS.5
In 2001,PTPN11was found to be one of the
causal genes of NS, and it was possible
to demonstrate that well-characterized
individuals with CFC did not have a muta-
tion in PTPN11.6–8 Furthermore, individu-
alswith CFCdid not carrymutations in the
HRAS gene, which causes CS, another
phenotypically similar condition.9 Identiﬁ-
cation of these 2 genes for NS and CS
suggested that CFC, NS, and CS were
separate, distinct conditions, with over-
lapping phenotypes.
The ﬁnal proof came in 2006 when 2
groups demonstrated that CFC is a het-
erogeneous disorder caused by muta-
tions in4differentgenes:BRAF,10,11MEK1,11
MEK2,11 and KRAS.10 These discoveries led
to the recognition that CFC was a distinct
syndrome separate from NS and CS
and also explained that the similarity
between them lay in a common un-
derlying molecular pathway, the Ras/
mitogen-activated protein kinase (MAPK)
pathway.1,12
MOLECULAR CHARACTERIZATION
The Ras/MAPK pathway is one of the
most studied signaling cascades and is
well known for its role in oncogenesis
and tumor progression. This pathway is
critically involved in cell proliferation, dif-
ferentiation, motility, apoptosis, and se-
nescence. CFC is caused by dysregulation
of the Ras/MAPK pathway due to het-
erozygous activating mutations in pro-
tein kinases, BRAF,10,11 MEK1,11 orMEK2.11
Mutations in KRAS, a small GTPase, have
been implicated as causing both CFC
and NS.10
Heterozygous BRAFmutations are found
in ∼75% of mutation-positive CFC individ-
uals.1 BRAF, an onco-protein, is a serine/
threonine protein kinase and one of
downstream effectors of Ras. Most BRAF
mutations are missense and found in
exons 6 and 12 and confer an activation of
TABLE 1 Continued
Clinical Specialty Recommendations
Cognitive and
behavioral
At risk for intellectual disability, delayed ﬁne and gross motor skills, emotional and
behavioral problems, atypical sensory processing, and speech/language impairments.
At diagnosis:
• Referral to early childhood services or local school system for needs assessment and
intervention.
• Speech and language evaluation including assessment of oral-motor functioning,
articulation, and expressive/receptive language ability. Speech and language therapy as
indicated based on evaluation. For severe delays, consideration of alternative or
augmentative communication systems.
• Physical therapy (speciﬁc attention to hypotonia and gross motor delay).
• Occupational therapy (speciﬁc attention to hypotonia, sensory integration, and vision
concerns).
• Behavioral therapy, mental health services, and/or alternative therapies may be
considered to address behavioral, sensory, motor, social, emotional, and/or
communication concerns.
Ongoing management:
• Continued evaluation and services by early childhood intervention programs in early
childhood.
• Upon school entry, physician referral for a full neuropsychological evaluation.
• Upon school entry, school professionals and families should collaboratively develop an
Individualized Education Plan (IEP) and/or other accommodation plan. Clarity should be
established regarding medical diagnosis and eligibility for special education services.
• If behavioral concerns exist, a functional behavior assessment may be indicated to
assist in development of a behavior intervention plan (speciﬁc attention to sensory
concerns, communication skills, and attentional ability).
Gastrointestinal At risk for feeding and/or swallowing difﬁculties, FTT, constipation, gastroesophageal
reﬂux, and intestinal malrotation.
At diagnosis:
• Nutrition assessment/growth measurements by primary physician.
• Refer to gastroenterologist in early infancy for feeding difﬁculties, gastroesophageal
reﬂux, and poor growth.
• If feeding difﬁculties are present, referral for feeding therapy evaluation and
recommendations.
• Evaluate for gastroesophageal reﬂux and swallowing dysfunction by swallowing studies,
pH studies, upper gastrointestinal series, and endoscopy studies as recommended by
gastroenterologist.
• Consider treatment with proton pump inhibitors for gastroesophageal reﬂux.
• Consider assisted feeding for FTT (nasogastric or gastrostomy tube), found to be
necessary in 40% to 50% with CFC. Surgical recommendations to be assisted by
gastroenterologist.
• If feeding difﬁculties are present, then refer for feeding therapy evaluation.
Ongoing management:
• Regular follow-up to monitor growth and nutrition.
• Continued feeding therapy if there are persistent feeding difﬁculties.
• Treatment of gastroesophageal reﬂux and constipation as needed as children get older
Growth/
endocrine
At risk for failure to thrive, short stature, GHdeﬁciency, GH resistance, anddelayedpuberty.
At diagnosis:
• Refer to endocrinologist between ages 2 and 3 y for growthmonitoring or earlier if there
are concerns about growth.
• Obtain thyrotropin, free thyroxine, IGF-1, and IGF-BP3 levels because thyroid and GH
abnormalities are seen in other RASopathies.
• Nutritional assessment/growth measurements by primary physician.
Ongoing management:
• Monitor growth carefully (height, weight, and head circumference at each visit) and
refer to appropriate specialists if signiﬁcant change in growth curves (eg,
endocrinologist, gastroenterologist, neurologist, or neurosurgeon).
• Regular follow-up by endocrinologist if growth failure, GH deﬁciency, or thyroid
hormone abnormality.
• If growth failure: thyroid function studies, celiac disease screening, GH stimulation
studies to be directed by endocrinologist.
• Monitor pubertal development beginning around age 10 y.
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the oncoprotein. The most common BRAF
mutations occur in exon 6 (p.Q257R), in
exon 12 at p.E501, and in exon 11
(p.G469E). Heterozygous mutations in
MEK1 (MAP2K1) and MEK2 (MAP2K2)
are present in ∼25% of CFC individuals
in which a gene mutation has been iden-
tiﬁed.1 The most common missense MEK
mutation is MEK1 p.Y130C. MEK1 and
MEK2 are threonine/tyrosine kinases,
with both isoforms having the ability to
phosphorylate and activate ERK1 and
ERK2. Functional studies of MEK mutant
CFC proteins have shown that all are
activating.11,13
CFC is typically the result of a de novo
heterozygous mutation. It is very rare
for individualswithCFC to reproduce.14
Germline mosaicism has yet to be
reported.
GENOTYPE/PHENOTYPE
CORRELATIONS
Few genotype–phenotype studies of
CFC have been performed to date. One
statistically signiﬁcant genotype–
phenotype correlation is the incidence of
pulmonic stenosis, which is present in
50% of individuals with CFC with a BRAF
gene mutation and 37% of those with
a MEK gene mutation.15 It also appears
that, while not statistically signiﬁcant,
MEK mutations may be associated with
a higher likelihood of prematurity, ven-
tricular septal defects, pectus deformity,
urogenital abnormalities, and dermato-
logical abnormalities,15,16 whereas BRAF
mutations may be more commonly
associated with hypertrophic cardio-
myopathy (HCM), atrial septal defects,
moderate to severe intellectual dis-
ability, and signiﬁcant feeding difﬁ-
culties.15
Among theRASopathiesasawhole, there
arerelativelywell-establishedgenotype–
phenotype correlations with respect to
cognitive development. Mutations associ-
ated with CFC and CS tend to correspond
to greater impairments in intellectual
and adaptive functioning thanmutations
TABLE 1 Continued
Clinical Specialty Recommendations
Musculoskeletal At risk for hypotonia with decreased muscle, scoliosis, pes planus, joint contractures, hip
dysplasia, and pectus deformities.
At diagnosis:
• Referral to a pediatric orthopedist.
Ongoing management:
• Radiograph of thoracolumbar spine, pelvis and lateral radiograph of cervical spine
depending on clinical ﬁndings of child.
• For those who are not ambulatory: AP radiographs of pelvis every 2 y to monitor for hip
dysplasia.
• Monitor for scoliosis.
• Spine MRI before any spinal surgery.
• Long-term follow-up with orthopedist as appropriate.
• Before orthopedic surgery, see hematologic recommendations.
• Bone density scan in young adults.
Ophthalmology At risk for ptosis, amblyopia, refractive errors, strabismus, cataracts, optic nerve hypoplasia, optic
atrophy, cortical visual impairment, delayedvisualmaturation, andabnormaldepthperception.
At diagnosis:
• Referral to a pediatric ophthalmologist.
• Early intervention as appropriate (ie, correction of ptosis, prescription glasses for
refractive errors or strabismus, patching for amblyopia).
Ongoing management:
• Follow-up every 6–12 mo or more frequently as recommended by ophthalmologist.
• Visual functional assessment by early childhood programs and vision resources for
poor vision and abnormal depth perception.
• In those with optic nerve abnormalities, MRI of brain should be obtained to screen for
malformations that could cause optic atrophy.
Otolaryngology/
audiology
At risk for narrow ear canals, impacted cerumen, hearing loss, and laryngomalacia.
At diagnosis:
• Audiologic evaluation.
• Refer to otolaryngologist for airway evaluation/management in the case of neonatal or
early respiratory issues.
• Referral to otolaryngologist for hearing loss management.
Ongoing management:
• Audiologic assessment every 2–3 y, or more frequently if necessary. Hearing aids as needed.
• Refer to otolaryngologist for impacted cerumen, abnormal audiologic testing, and hearing loss.
• Prompt treatment of ear infections to minimize hearing loss.
• Otolaryngology follow-up for management of airway.
Renal/
genitourinary
At risk for kidney malformation, vesicoureteral reﬂux, and cryptorchidism.
At diagnosis:
• Renal ultrasound to evaluate for structural renal anomalies.
• Refer to urologist and endocrinologist if cryptorchidism present.
Ongoing management:
• As indicated by urologist.
Hematology/
oncology
At risk for easy bruising, von Willebrand disease, and thrombocytopenia.
At diagnosis:
• Obtain history regarding easy bruising or bleeding problems.
• If easy bruising or bleeding problems are present, screen with CBC, platelet count,
platelet function study, and von Willebrand screen.
• Refer to a hematologist for an abnormal CBC.
Ongoing management:
• If evidence of easy bruising or bleeding appearswith time, then screenwith CBC, platelet
count, platelet function study, and von Willebrand screen.
• If patient requires surgery, screen with the above testing before surgery if not already done.
• For those on divalproex sodium for seizures, obtain platelet count every 6 mo.
Dental At risk for malocclusion, posterior crossbite, and bruxism.
At diagnosis:
• Dental evaluation.
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associated with NS.17–19 Although some
reports indicate that individuals with
MEK mutations have milder intellectual
disabilities when compared with those
with BRAF mutations, the numbers are
still too small to reach statistical signif-
icance.15,20 There is some preliminary
evidence to suggest that the most com-
mon BRAF missense mutation, p.Q257R,
may be associated with fewer develop-
mental delays than other BRAF muta-
tions.19 Further studies are required to
determine if this will be conﬁrmed.
KRAS mutations can be found in indi-
viduals with the clinical diagnosis of
both CFC and NS.10,21,22 In general, in-
dividuals with a KRAS mutation have
mild to moderate intellectual disability,
dysmorphic facial features, short stat-
ure, dermatologic abnormalities, and
ophthalmologic abnormalities. Regard-
less of phenotypic assignment, it is
essential to establish the molecular
etiology of all individuals with CFC to
provide appropriate medical care. Ad-
ditionally, the molecular conﬁrmation
will be important for genetic counseling
and understanding of recurrence risk
and natural history.
GENETIC TESTING FOR CFC
SYNDROME
All individuals suspected to have CFC
should undergo examination and mo-
lecular testing directed by a geneticist
who can determine the most appro-
priate and cost effective type of testing
and can provide explanations of the
results obtained to the family and other
health providers. Current commercial
tests for themolecular diagnosis of CFC
include the following: (1) next-generation
sequencing of multigene panels of the
common RASopathy genes, (2) individual
single gene sequencing, and (3) chro-
mosome microarray to screen for copy
number abnormalities. Multigene panel
testing is usually thepreferred initial test
and will detect a mutation in ∼70% to
90% of individuals with the clinical di-
agnosis of CFC.15 If panel testing is not
available, sequential gene testing is
recommended, beginning with BRAF,
MEK1 and MEK2, and KRAS. In the event
that a variant of uncertain signiﬁcance is
identiﬁed, parental testing and physical
examination is recommended to deter-
mine if the variant was inherited. If
molecular testing of the CFC genes is
negative, the geneticist can arrange for
testing of the other Rasopathy genes if
they have not yet been done and con-
sider other conditions in the differential
diagnosis (Table 2). If these are negative,
the geneticist may consider a chromo-
some microarray analysis to screen for
microdeletions/microduplications that
can be associated with phenotypes that
partially overlapwith CFC.23–26 If all of the
above are negative, the geneticist/genetics
provider can consider whole exome or
genome sequencing for diagnosis.
CLINICAL DESCRIPTION WITH
DIFFERENTIAL DIAGNOSIS
Clinical features of CFC begin in the pre-
natal period with ultrasound ﬁndings of
increased nuchal lucency and, some-
times, cystichygroma.27,28Polyhydramnios
is very common (77%) and premature
TABLE 1 Continued
Clinical Specialty Recommendations
Ongoing management:
• Appropriate hygiene.
• Restorative care.
• Orthodontic treatment as needed.
CBC, complete blood cell; FTT, failure to thrive.
TABLE 2 Differential Diagnosis of CFC and Other Conditions
Syndrome Common Features With CFC Differences With CFC
NS Hypertelorism, downslanting palpebral ﬁssures,
ptosis, short stature, relative macrocephaly, PVS,
HCM, atrial septal defect, and some with cognitive delay.
Facial features less coarse, lower incidence of
severe feeding problems, fewer cutaneous
features such as follicular hyperkeratosis,
sparse eyebrows, ulerythema ophryogenes,
and less incidence of marked cognitive delay.
CS Coarse facial features, curly hair, broad nasal bridge,
downslanting palpebral ﬁssures, epicanthal folds,
PVS, HCM, pectus deformity, short stature, and
intellectual disability.
Papillomata of the face or perianal regions,
multifocal atrial tachycardia, ulnar deviation
of wrist and ﬁngers, and loose skin.
NS with multiple lentigines
(formerly LEOPARD syndrome)
Short stature, hypertelorism, PVS, HCM, and some
with cognitive delay.
Multiple skin lentigines, frequent sensorineural
deafness, cardiac conduction abnormalities, and
less incidence of marked cognitive delay.
Baraitser-Winter syndrome Hypertelorism, ptosis, short stature, and cognitive
delay.
Iris coloboma, lissencephaly, pachygyria, aortic valve
anomalies, and facial features less coarse.
NS with loose anagen hair Triangular facies, hypertelorism, high forehead, sparse
thin hair, short stature, eczema, dry skin, and
macrocephaly.
After infancy facial features less coarse, mitral valve
dysplasia, and less incidence of marked cognitive delay.
STATE-OF-THE-ART REVIEW ARTICLE
PEDIATRICS Volume 134, Number 4, October 2014 e1153
by guest on June 3, 2016Downloaded from 
birth is present in up to a half of preg-
nancies.29
Craniofacial characteristics, coupled
with features such as cardiac disease,
feeding difﬁculty, and developmental
delay, are often the ﬁrst diagnostic
clues after birth suggesting the di-
agnosis of CFC. In 2002, a CFC index
was developed based on 82 clinical
traits to assist with diagnosis.30 How-
ever, at present, there are no pa-
thognomonic or obligatory features
uniquely associated with CFC that can
aid in making a deﬁnitive clinical di-
agnosis.
The head and face are characterized by
macrocephaly/relative macrocephaly,
tall forehead with bitemporal narrow-
ing, increased facial width and depth,
coarse facial features, andsmall chin.3,31–33
Sparse, curly, and friable hair, with
sparse or absent eyebrows with hy-
perkeratosis (ulerythema ophryogenes)
are very common in CFC and occur
with greater frequency than in other
RASopathies.3,16,32 Ocular features in-
clude ptosis, hypertelorism, downslant-
ing palpebral ﬁssures, and epicanthal
folds. The nose is often short with a
broad nasal base, bulbous tip, and
anteverted nares.3,31,32 The mouth is
wide with a deeply grooved philtrum
and Cupid’s bow contour of the upper
vermillion border.32 The palate is nar-
rowand high archedwith a short, broad
or biﬁd uvula.32 Ears are posteriorly
angulated and low set. With age, the
face may become coarser and facial
characteristics less pronounced (Fig 1 A
and B).15,32
Many of the clinical features of CFC
overlapwith those of NS and CS (Table 2).
Other conditions to be considered in
the differential diagnosis of CFC include
NS with multiple lentigines, Baraitser-
Winter syndrome, and NS with loose
anagen hair. Because of differences in
the medical management, long-term
prognosis, and genetic risks, obtaining
the correct diagnosis is very important
among these syndromes with over-
lapping features.
CARDIAC ISSUES
Nearly 75% of individuals with CFC have
cardiovascular involvement of various
kinds (Table 3).15,32 As soon as clinical
ﬁndings of CFC are recognized or a di-
agnosis of CFC is conﬁrmed, a consul-
tation with a pediatric cardiologist and
echocardiography should be obtained.
The most common cardiac problem is
pulmonary valvular stenosis (PVS), pres-
ent in ∼45% of individuals, sometimes
with a dysplastic pulmonary valve.15,29,32
PVS may occur alone or concomitantly
(in nearly 20%) with other cardiac de-
fects, such as atrial septal defect or
HCM. The cardiologist may consider
cardiac catheterization and balloon
angioplasty if the PVS is severe, al-
though it is not always successful.
Surgery may also be recommended
by the cardiologist in preference to
balloon angioplasty, especially if there
are multiple cardiac defects. The sur-
gery might include pulmonary valvotomy
and correction of other defects as
necessary.
HCM, present in nearly 40%of individuals
with CFC, can occur in infancy and have
a wide variation in severity, sometimes
rapidly progressive, even resulting in
death or cardiac transplantation.34 Oth-
ers have only mild cardiac thickening
that is not progressive and may improve
with time. One adult with HCM detected
shortly before his death at age 21 years
also had pulmonary hypertension and
pulmonary vascular changes (Grade 3
Heath/Edwards) on autopsy.32 In gen-
eral, children and adults with CFC and
mild HCM may require only periodic
reevaluation with their cardiologist.
Those with more signiﬁcant HCM could
require treatment with b-blocker med-
ications or surgical procedures includ-
ing myomectomy to decrease outﬂow
obstruction.
Other forms of heart disease (Table 3)
seen in CFC are atrial sepal defect (18%
to 28%), ventricular septal defect (11%
to 22%), and other rarer defects such
as mitral valve dysplasia, coarctation
of the aorta, and subaortic stenosis.29,31,32
Each of these conditions and those in
Table 3 are managed by a cardiologist
who determines reevaluation frequency
and plans interventions as necessary
including cardiac catheterization, med-
ication management, device closure
for septal defects, and surgical pro-
cedures.
ArrhythmiasareuncommoninCFC,when
compared with CS where they occur
more frequently.2,10,15,35–37 Types of
arrhythmias previously documented
include the following: supraventric-
ular tachycardia, atrioventricular
block, and Wolff–Parkinson–White.15
Consultation with a cardiologist is
recommended for management of
arrhythmias.
Little is known about the natural history
of heart disease in CFC and whether
heart abnormalities such as myocar-
dial thickening/dysfunction (HCM) can
develop at older ages. All patients with
CFC, even those who have had previous
normal echocardiograms or under-
went surgical repairof congenital heart
defects as young children, should have
periodic cardiac reevaluation by a car-
diologist.
DERMATOLOGIC MANIFESTATIONS
Dermatologic manifestations are car-
dinal features of CFC, important for
clinical diagnosis and differentiating
CFC fromotherRASopathies.36 Although
the severity and type of ectodermal
involvement varies (Table 3), virtually
all CFC individuals develop some form
of cutaneous involvement and for this
reason, dermatologic consultation and
follow-up are recommended.16,22,38 Among
the manifestations are wavy or curly
scalp hair, with sparse hair at the temples,
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poor hair growth, and sparse arm
and leg hair. Ulerythema ophryogenes,
characterized by brow erythema with
loss of follicles, causes sparse orabsent
eyebrows with only 10% of individuals
having normal eyebrows.16 Numerous
acquired melanocytic nevi are striking
features of CFC, with this ﬁnding less
common in other RASopathies.39 It is not
uncommon for individuals to develop
over 100 nevi as they age, with the nevi
not restricted to light-exposed areas.16
To date, there are no reports ofmalignant
transformation of pigmented lesions in
CFC.
Keratosis pilaris (follicular hyperkera-
tosis of the extremities and/or face)
is also seen in the majority of cases.
Individuals with CFC have a high rate of
heat intolerance, may sweat exces-
sively, and develop axillary body odor
due to hyperkeratosis. Other dermato-
logic ﬁndings in CFC include dry skin,
eczema, dystrophic nailswith rapid nail
growth, generalized hyperpigmentation,
ear lobe creases, acanthosis nigricans,
hyperplastic nipples, and creases on the
ﬁngertips. Nasal and perianal papillo-
mata, typically seen in CS, are uncom-
mon inCFC. Infantilehemangiomas,seen
in 25% of CFC individuals, higher than
otherRASopathies, havea similar natural
history to those in thegeneral population.
Some skin manifestations evolve over
time and are usually seen in adolescence
and adulthood. Palmo-plantar calluses
FIGURE 1
A, Patientwith CFC (BRAF p.Q257Rmissensemutation) at (from left to right) 4 days, 3months, 3 years, 5 years, 7 years, 12 years, 14 years, and 16 years. B, Patient
with CFC (MEK2 p.F57C missense mutation) at (from left to right) 1 day, 3 years, 7 years, 9 years, 13 years, 14 years, 16 years, and 20 years.
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can develop especially in pressure areas,
and peripheral lymphedema is occa-
sionally present, most often affecting the
lower limbs.32 Those with lymphedema
canbe referred to vascular/lymphedema
clinics for management. Early treatment
of skin infections is recommended in
those with lymphedema.
NEUROLOGIC FINDINGS
Neurologic abnormalities are univer-
sallypresent inCFCandrange frommild
to severe.40 Hypotonia, motor delay,
speech delay, and learning disability can
be considered main features (Table 3).
Neurologic examination typically will
demonstrate macrocephaly, hypotonia,
ocular abnormalities, corticospinal tract
ﬁndings, touch sensitivity, and tactile
defensiveness.29,41,42 Peripheral neurop-
athy has been rarely documented in CFC,
but may be underdiagnosed.43,44 Brain
MRI studies reveal structural malforma-
tions in 9% to 85% of patients with CFC.42
Abnormalities include ventriculomegaly,
hydrocephalus, cortical atrophy, prom-
inent Virchow-Robin spaces, and abnor-
mal myelination.40,42 Other structural
anomalies such as type I Chiari mal-
formation, arachnoid cyst, gray mat-
ter heterotopia, corpus callosum
abnormalities, cerebellar calciﬁcation,
and periventricular leukoencephalopathy
have been reported.40–42
It has been suggested that central
nervous system malformations are
underreported in CFC because only
38% to 50% of children have had brain
MRI or computed tomography scans.42,44
The fact that many children with CFC
do have structural brain malforma-
tions suggests the need for brain im-
aging in patients with CFC, as ﬁnding
morphologic brain changes could
lead to better understanding of the
individual’s neurologic ﬁndings or un-
derlying diagnosis. For example, indi-
viduals with NS have relatively few
central nervous system malformations,
and a brain MRI with some of the
above structural abnormalities may
suggest a diagnosis of CFC rather
than NS.
Unlike other RASopathies, seizures of
various types may affect ∼40% to 50%
of children with CFC.29,40 Seizure types
may include complex partial, general-
ized tonic-clonic, absence seizures, and/
or infantile spasms.40 Infantile spasms,
which are relatively rare in the general
population, are a common seizure type
in CFC.40,45,46 When there is clinical sus-
picion for infantile spasms or other
seizures, an urgent sleep EEG should be
obtained along with consultation with
a neurologist. Prompt diagnosis and
subsequent treatment is critical in
TABLE 3 Summary of Occurrence of Speciﬁc Clinical Manifestations in CFC
Common May Occur Rare
Cardiac
Pulmonary valve stenosis Supravalvular pulmonary
stenosis
Aortic root dilation
HCM Bicuspid aortic valve Restrictive cardiomyopathy
Atrial septal defect Coarctation of the aorta Ebstein’s anomaly of the tricuspid
valve
Ventricular septal defect Coronary artery abnormality
Mitral valve anomalies Aortic valve thickening
Rhythm disturbance
Dermatologic
Ulerythema ophryogenes Acanthosis nigricans Papillomas
Keratosis pilaris/hyperkeratosis Hyperplastic nipples Multiple café-au-lait macules
Acquired melanocytic nevi Creases on the ﬁngertips
Hemangiomas Foot callosities
Fast growth of nails Lymphedema
Sparse arm and leg hair Generalized hyperpigmentation
Prepubertal axillary odor
Poor hair growth on scalp
Ear lobe creases
Xerosis/eczema
Neurologic
Macrocephaly Myelination abnormality Gray matter heterotopia
Hypotonia with motor delay Virchow-Robin spaces Abnormal corpus callosum
Ventriculomegaly/
hydrocephalus
Type I Chiari malformation Arachnoid cyst
Neurocognitive delay Optic nerve hypoplasia Periventricular leukoencephalopathy
Seizures Corticospinal tract ﬁndings Peripheral neuropathy
Gastrointestinal
Suck/swallowing dysfunction Intestinal malrotation Intestinal atrophy
Gastroesophageal reﬂux Anal stenosis Antral narrowing
Constipation Inguinal hernias Anal papilloma
Fetal polyhydramnios Fecal impaction Hepatomegaly
Gastrostomy tube feedings Functional megacolon Fatty liver
Oral aversion Umbilical hernia Crohn disease
Musculoskeletal
Pes planus Elbow contracture Abnormal tibial torsion
Hand dysfunction Kyphosis Lordosis
Scoliosis Femoral retroversion Torticollis
Hip dysplasia Hip contractures Hallux valgus
Knee contractures Pectus deformity Equinus
Shoulder dysfunction Leg pains Radial head subluxation
Dysfunctional gait Wrist instability
Osteopenia Short metatarsals
Hypotonia
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infantile spasms to avoid permanent
neurodevelopmental sequelae. Seizures
in CFC are often refractory to medica-
tions, requiring several anticonvul-
sants.40,46 Polytherapy may lead to an
increased risk of medication-related
side effects that could impact individu-
als with CFC who already have learning
disability and developmental delay.
Long-term neurologic reevaluation can
be organized by the neurology consul-
tant on the basis of need for ongoing
seizure management.
COGNITIVE AND BEHAVIORAL
Relatively few studies have reported on
neuropsychological sequelae of CFC.
Skills in intellectual, motor, social, com-
municative, and behavioral functioning
vary widely. Intellectual disability is
present in 90% to 100% of individuals
with CFC,30,40 yet IQs in the low average to
average rangehave been reported among
a few individualswith BRAFmutations.47,48
Gross motor skills tend to be more
delayed in the early years (ie, birth to age
6 years) than ﬁne motor skills,19 perhaps
due to the high incidence of hypotonia.
Mean age of walking without assistance
is reported to be around 3 years, al-
though∼18%of individualswith CFC are
unable to achieve independent walk-
ing.40 Language abilities range from
limited nonverbal communication to
capacity to speak in full sentences. On
average, children with CFC speak their
ﬁrst word around 2 years of age, al-
though 9% to 31% remain nonverbal.19,40
Progress in basic language development
can continue well into adolescence.
Receptive language ability is typically
stronger than expressive language.19
Many families report using simple sign
language or assistive technologies to
facilitate communication.29
In academic settings, virtually all chil-
drenwith CFC receive special education
servicessuchasspeech/language therapy,
occupational therapy, physical therapy,
and/or assistance of a paraprofessional.19
School performance can vary from pro-
found disability (with minimal/static de-
velopmental progress) to mild disability
(with achievement of basic reading,
writing, and math skills).40 Behaviorally,
many families report concerns related
to irritability, short attention span, stub-
bornness, and obsessive or aggressive
behaviors.43 Sensory processing prob-
lems (eg, tactile defensiveness) and a
heightened risk for autism spectrum dis-
order traits have also been reported.29,49
Sleep problems are common, including
poor sleeping patterns, night sweating,
sleep apnea, and night terrors.29
Although research to evaluate the ef-
fectiveness of behavioral treatments in
CFC is currently lacking, studies of indi-
viduals manifesting similar character-
isticssuggest likelyavenuesforsuccessful
intervention. Therapies focused on ex-
panding functional communication (eg,
interventions incorporatingsignlanguage,
discrete-trial training or naturalistic
[“milieu”] teaching) have demonstrated
efﬁcacy in individuals with intellectual
disabilities and those with autism spec-
trum disorders.50,51 Parent-training inter-
ventions to manage behavior or promote
speciﬁc skills have also proven success-
ful.52,53 Approaches such as personalized
schedules and functional behavior as-
sessments have demonstrated ef-
fectiveness in children with similar
neurologic and behavioral impair-
ments.54,55 Finally, treatments targeting
difﬁculties with sensory processing
have the potential to improve function-
ing.52 Given the wide variability in clini-
cal characteristics in CFC, tailoring
intervention to each child’s unique de-
velopmental trajectory is essential, as is
coordinated implementation of services
across the home, medical, and educa-
tional settings.
GASTROINTESTINAL AND GROWTH
ISSUES
Failure to thrive and poor growth in
infancy are almost universal in CFC.2,36
These are usually accompanied by se-
vere feeding problems including gas-
troesophageal reﬂux, suck/swallow
dysfunction, and oral aversion (Table 3).
The swallowing difﬁculties are reﬂected
early by prenatal polyhydramnios that,
after birth, is followed by difﬁculty in
maintaining adequate oral caloric in-
take.41,56 Prolonged supplemental feedings
via nasogastric tube feedings or
gastrostomy tube placement are com-
mon (40% to 50%) in CFC. Many still re-
quire assisted feeding in late childhood
and adolescence.29 Respiratory com-
plications such as choking, aspiration
pneumonia, and chronic raspy breath-
ing are also related to the swallowing/
oropharyngeal difﬁculties. Oral aver-
sion and sensory integration difﬁcul-
ties with solid foods can persist into
adulthood.
Severe feeding difﬁculties, gastroesoph-
ageal reﬂux, and failure to thrive in an
infant with facial features similar to NS
along with cardiac disease should
suggest the possible diagnosis of CFC.
An early evaluation by a gastroenter-
ology specialist is recommended in
infancy or at the time of diagnosis to
allow guidance in testing and deci-
sions regarding necessity of supple-
mental feedings or surgeries such as
fundoplication. Feeding therapy is sug-
gested at the ﬁrst sign of oral aversion.
Treatment of gastresophageal reﬂux
with proton pump inhibitors may be of
some value.
Constipationrelated to intestinaldysmotility
is often seen in children with CFC and
can remain a lifelong problem. Gas-
troenterologists can differentiate the
constipation caused by intestinal dys-
motility from other less common con-
ditions such as intestinal malrotation,
functional megacolon, anal stenosis, or
rarely intestinal atrophy.41,44,57 Constipa-
tion can continue into adulthood and
follow-up by a gastroenterologist may be
helpful in planning a satisfactory bowel
regimen.
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ENDOCRINE ISSUES
Short stature is a common feature in all
RASopathies.1,58,59 This is not surpris-
ing since the Ras/MAPK pathway plays
a major role in mediating the intra-
cellular signaling of Insulin-like Growth
Factor (IGF-1), which mediates postnatal
growth effects of growth hormone (GH).
In addition, MAPK activation is important
in regulating the proliferation of pitui-
tary somatotrophs that synthesize and
release GH.60 Therefore, dysregulation of
the Ras/MAPK signaling pathway may
contribute, along with other intrinsic
and extrinsic factors, to growth failure
and short stature.59
It is estimated that two-thirds of children
with CFC have short stature.1,3,4,58,61,62
The exact cause of short stature is not
well established; some individuals may
have GH deﬁciency, whereas some may
have GH resistance. In addition, inade-
quate nutrition, due to the high prevalence
of feeding problems in CFC, might con-
tribute to failure to thrive, poor growth,
and possibly IGF-1 deﬁciency. Although
GH therapy is approved by the Food and
Drug Administration for short stature in
NS, the use of GH in CFC has not been
studied. For children with NS, GH use
may result in short-term improvement
in growth velocity and a modest gain in
ﬁnal adult height.63 Studies on the ben-
eﬁts of GH therapy in CFC are needed.
Currently, the only approved use of GH in
CFC is for those with documented GH
deﬁciency.
Monitoring linear growth throughout
infancy and childhood is essential to
identify growth concerns early. Indi-
viduals with height consistently below
the thirdpercentile orwithpoor growth
velocity should be evaluated for growth
failure. If weight gain is suboptimal and
there are feeding difﬁculties and poor
caloric intake, gastrointestinal evalua-
tion is warranted.
Recent reportshave suggestedahigher
incidenceof autoimmunity in thosewith
a RASopathy.64 Because autoimmune
thyroiditis is common in the general
population, measurements of thyroid
function are recommended at diag-
nosis. Only a few instances of hypo-
thyroidism have been documented in
CFC,29 so follow-up thyroid testing can
be decided by an endocrinologist. Au-
toimmunity in CFC is an area that could
beneﬁt from future research.
Puberty may be delayed in individ-
uals with CFC. Health care provid-
ers should be mindful of monitoring
Tanner staging annually beginning
at 10 years of age. Endocrine eval-
uation is appropriate if onset of pu-
berty is delayed beyond age 12 to 13
years.
MUSCULOSKELETAL CONDITIONS
Musculoskeletal ﬁndings are seen in all
RASopathies but are particularly prom-
inent in CFC. Global hypotonia is evident
on clinical examination especially in the
newborn period and is manifested by
delayed motor skills, muscle weakness,
and decreased muscle bulk. As children
growolder,muscleweakness appears to
gradually improve, although individuals
still may have gross motor delays.65,66
Skeletal muscle strength does not ap-
pear to completely normalize andmuscle
bulk usually remains underdeveloped,
and may actually decrease in older
individuals. The origin of hypotonia in
CFC is unclear, as it may arise from
central nervous system dysfunction,
muscle pathology, or a combination of
the two. Skeletal muscle biopsies of
CFC demonstrate relatively normal
architecture, but abnormal muscle ﬁ-
ber size and variability, with a pre-
dominance of type 2muscle ﬁbers.67 In
addition, some preliminary observa-
tions have described individuals with
CFC with oxidative phosphorylation
dysfunction and muscular coenzyme
Q10 deﬁciency.68,69
Orthopedic conditions in CFC (Table 3)
occur with high frequency and cause
signiﬁcant disability,65 so referral to an
orthopedist is recommended at di-
agnosis. Individuals may have scoliosis
and/or kyphosis, pectus excavatum and/
or carinatum, joint hyperextensibility, joint
contractures, pes planus, and dysfunc-
tional gait.29,65 The need for a walker is
not uncommon.
Scoliosis occurs in∼33% of individuals
with CFC and mimics idiopathic or
neurogenic scoliosis, without evidence
of overt vertebral malformations.65
Type I Chiari malformations have been
found on MRI studies, and such mal-
formations have been linked to the
development of scoliosis.65,70 Pes planus
or planovalgus is seen in two-thirds of
individuals with CFC and tends to be
more severe than in the general pop-
ulation, with signiﬁcant forefoot valgus.65
Treatment is generally nonsurgical;
however, those with severe deformity
and/or signiﬁcant functional impair-
ment may require surgical correction.
Osteopenia has been anecdotally re-
ported, and there is biochemical ev-
idence of increased bone resorption
in several RASopathies, including CFC;
however, the clinical consequence of
increased bone resorption in this pop-
ulation is not yet known.58
OPHTHALMOLOGIC FEATURES
Ocular manifestations in CFC occur in
the majority of individuals.11,33,37,40,71
Commonly reported ﬁndings include
strabismus, refractive errors, nystag-
mus, ptosis, and optic nerve hypopla-
sia.11,33,40 Craniofacial abnormalities
related to the eyes include hyper-
telorism, epicanthal folds, and hypo-
plastic supraorbital ridges.71 A recent
study of a large cohort of mutation-
positive individuals with CFC identiﬁed
the above ﬁndings, as well as problems
with depth perception and reduced vi-
sual acuity.33 A number of children
undergo strabismus correction in
early infancy or early childhood, with
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exotropia being more common. Re-
fractive errors include myopia, hy-
peropia, and astigmatism. Nystagmus
is present in a number of individ-
uals, some of whom adopt head pos-
tures to dampen the nystagmus that
may diminish with age. Amblyopia
is a common ﬁnding. Cataracts have
been reported in one individual
who required no intervention.11 Fun-
dus evaluation reveals optic nerve
changes ranging from hypoplastic
optic disks to small but normal ap-
pearing optic disks, tilted and irregular
optic disk margins, and peripapillary
pigmentation and atrophy.33 Ab-
normalities of the anterior seg-
ment, fovea, macula, peripheral retina,
or blood vessels are usually not
present.
Although the majority of individuals
with CFC have ocular problems, most
are amenable to treatment. These in-
clude ptosis, refractive errors, and
strabismus. Proper treatment depends
on early referral for ophthalmologic
assessment (Table 1). In those with
optic nerve problems, MRI brain im-
aging is helpful to assess for brain
abnormalities such as type I Chiari
malformation or hydrocephalus that
could result in optic atrophy.
OTOLARYNGOLOGY/AUDIOLOGY
MANIFESTATIONS
Externalearabnormalitiessuchaslowset,
posteriorly rotated ears with upturned
lobes are often seen in CFC.11,33,37 Other
features include ear lobe creases,
small indentations behind the ears, or
ear pits.16,36,71 Narrow external audi-
tory canals, excess cerumen, and ne-
cessity for ear tube placements are
common.29 Sensitivity to loud sounds
and hearing loss have also been
reported.15 No systematic evaluation
has yet been done to determine the
prevalence or type of hearing loss,
which affects many patients with CFC.
Therefore, audiologic assessment and
otolaryngology consultation is recom-
mended on diagnosis. Laryngotracheal ab-
normalities such as laryngotracheomalacia
and laryngeal clefts are also seen in
CFC. Some young infants have required
tracheostomy because of marked
laryngomalacia41 and require long-term
care by an otolaryngologist (Table 1).
RENAL/GENITOURINARY FINDINGS
Renal and genitourinary abnormalities
occur in ∼17% to 33% of individuals
with CFC.15,29 Renal cysts, medullary
nephrocalcinosis, nephrolithiasis,
hydronephrosis,andhydroureteronephrosis
have all been reported.41,56 Cryptor-
chidism has been found in two-thirds of
male patients, similar to the incidence in
NS.15
HEMATOLOGY/ONCOLOGY
CONDITIONS
Unlike NS, easy bruising and bleeding
problems have not been reported
as frequently in CFC. There is 1 report of
transient thrombocytopenia in a new-
born and 1 with a history of frequent
epistaxis.32 One individual has been
reported with von Willebrand dis-
ease.29 If easy bruising and bleeding
problems are present on diagnosis or
appear with time, screening for plate-
let abnormality and von Willebrand
disease is recommended.
Although the mutations causing CFC
are in a well-known oncogenic path-
way, it is unclear if individualswith CFC
are at an increased risk for malig-
nancies. In ∼200 individuals with CFC
reported in the literature, 3 have been
found to have acute lymphoblastic
leukemia,10,14,72 one with non-Hodgkin
lymphoma,73 and one with large B-cell
lymphoma. One individual with CFC
(BRAFmutation) had a hepatoblastoma,
possibly the result of postcardiac
transplant immunosuppression.34 Addi-
tional studies are needed to accurately
assess the risk of malignancy in CFC.74
ORAL/DENTAL ISSUES
Individuals with CFC have a character-
istic dental phenotype including mal-
occlusion with open bite, posterior
crossbite, high labial frenal attach-
ment, and high-arched palate.33 Oral
habits may include tongue thrusting,
bruxism, and open mouth posture.
Dental development typically follows
the timing present in the general pop-
ulation with normal eruption patterns,
although ∼10% of individuals may be
delayed. Dental crowding may be seen,
but not at a higher frequency than the
general population. It is rare to observe
hypodontia, gingival hyperplasia, or
supernumerary teeth.29 Dental caries
are typical though the enamel is clini-
cally normal. Overall, there is not a
unique dental pathology requiring
speciﬁc treatment, but routine dental
examinations, appropriate hygiene,
restorative care, and orthodontic care
if needed are recommended. Due to
neurocognitive delay and oral aversion,
some may exhibit anxiety during dental
examinations. Thus, these individuals
should be seen early and often to ac-
custom them to dental treatment.
SUMMARY
This report provides health pro-
fessionals with current information
with regard to the diagnosis and best
practices of care for individuals with
CFC (Table 1). It is important to un-
derstand that CFC is a variable and
genetically heterogeneous disorder
caused by mutations of genes in the
Ras/MAPKpathway. LikeotherRASopathies,
recognizable facial features, congeni-
tal heart disease, and short stature
characterize CFC. In addition, CFC also
has cutaneous and neurologic involve-
ment. Because of the many aspects
of CFC described herein, multidisci-
plinary care is essential. The prog-
nosis of many aspects of CFC is still
unknown, and full understanding of
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care expectations during childhood and
adulthood is yet to be established.
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